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Abstract 
  
Background: Despite moderate improvements in outcome of glioblastoma after first-line treatment 
with chemoradiation recent clinical trials failed to improve the prognosis of recurrent glioblastoma. In 
the absence of a standard of care we aimed to investigate institutional treatment strategies to identify 
similarities and differences in the pattern of care for recurrent glioblastoma. 
Methods: We investigated re-treatment criteria and therapeutic pathways for recurrent glioblastoma of 
8 neuro-oncology centres in Switzerland having an established multidisciplinary tumour-board 
conference. Decision algorithms, differences and consensus were analysed using the objective 
consensus methodology.  
Results: A total of 16 different treatment recommendations were identified based on combinations of 8 
different decision criteria. The set of criteria implemented as well as the set of treatments offered was 
different in each centre. For specific situations, up to 6 different treatment recommendations were 
provided by the 8 centres. The only wide-range consensus identified was to offer best supportive care 
to unfit patients. A majority recommendation was identified for non-operable large early recurrence 
with unmethylated MGMT promoter status in the fit patients: here bevacizumab was offered. In fit 
patients with late recurrent non-operable MGMT promoter methylated glioblastoma temozolomide 
was recommended by most. No other majority recommendations were present. 
Conclusion: In the absence of strong evidence we identified few consensus recommendations in the 
treatment of recurrent glioblastoma. This contrasts the limited availability of single drugs and 
treatment modalities. Clinical situations of greatest heterogeneity may be suitable to be addressed in 
clinical trials and second opinion referrals are likely to yield diverging recommendations. 
 
 
Keywords: recurrent glioblastoma, diagnostic nodes, objective consensus, decision making, re-
treatment criteria 
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Introduction 
Glioblastoma is the most common and devasting primary brain tumour with an annual incidence of 
about three per 100000 [1] persons. It is associated with great morbidity and early mortality. Even 
after multimodal treatment with temozolomide chemoradiation (RT/TMZ→TMZ) progression-free 
survival (PFS) and overall survival (OS) remain poor with 6.9 and 14.2 months, respectively [2]. 
Recently, four large phase III trials failed to improve outcome after first-line therapy in terms of OS [3-
6]. Hence, effective salvage treatment of recurrent glioblastoma remains a demanding problem in 
neuro-oncology.  
The oral alkylating agent TMZ is widely used for the treatment of recurrent glioblastoma (TMZ re-
challenge) [7-11]. However, the optimal dosing schedule and the minimal time interval from first line 
TMZ are unknown. This topic was investigated in a single prospective phase II trial using a 
metronomic TMZ schedule [9]. Patients with a tumour recurrence at least three months after RT/TMZ 
or two months after completion of RT/TMZ and six maintenance cycles of TMZ reached modest PFS 
rates after six months (PFS-6) of 27.3% and 35.7%, respectively. Recently, two dose-intensified TMZ 
schedules have been prospectively investigated at first relapse after at least two cycles of 
maintenance TMZ after RT/TMZ to avoid interference with pseudoprogression [11]. None of the 
regimes were superior with a median time to treatment failure of 1.8 months [Arm A: one week on 
(120 mg/m2 per day)/one week off] and 2.0 months [Arm B: three weeks on (80 mg/m2 per day)/ one 
week off], respectively. However, methylation of the MGMT promoter was a strong positive prognostic 
factor of PFS-6 (methylated 39.7% versus unmethylated 6.9%) [11]. Small targeted drugs like 
enzastaurin or cediranib failed to show benefit in recent phase III trials when compared to lomustine in 
recurrent glioblastoma [12, 13]. Therefore, lomustine has advanced to a widely used alkylating drug 
either alone or in combination whenever TMZ is not considered to be appropriate for the treatment of 
recurrent glioblastoma [14, 15]. In contrast to the European Union, bevacizumab, an anti-angiogenic 
agent targeting VEGF-A, has been approved in selected countries (i.e. North America, Switzerland) 
for the treatment of recurrent glioblastoma based on uncontrolled phase II studies [16, 17]. 
Due to the limited efficacy of second-line systemic treatment, focal strategies with re-operation and re-
irradiation have also been introduced as salvage treatments. However, little evidence for these 
therapies is available as most studies investigated only small or retrospective patient cohorts [18-25]. 
Furthermore, availability of stereotactic radiotherapy or radiosurgery and financial resources of health 
care systems account for significant differences in use between countries and even national regions.  
As effective treatment options are scarce and controlled trials are rare for recurrent glioblastoma, 
therapeutic decisions are mostly based on low level evidence [26]. Beyond evidence, experience 
(eminence-based medicine) may provide additional guidance. Possibly, further information can be 
extracted from the community, for example as patterns of care studies [27]. Patterns of care studies 
often rely on specific scenarios which are presented to participants, these are then analysed; the 
limitation being that the answers are restricted to only these specific scenarios. When the collected 
information is appropriately formatted [28], e.g. decision trees are collected, patterns of practice can 
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be analysed for multiple combinations of parameters [29]. In the setting of low evidence for salvage 
treatment we aimed to collect treatment algorithms from Swiss neuro-oncological centres which 
derive their treatment recommendations from multidisciplinary tumour boards. The collected 
information was used to perform a comprehensive patterns care and patterns of algorithms analysis 
for the treatment of recurrent glioblastoma. 
 
Materials and Methods 
Based on specific parameters (characteristics of the patient and the disease) recommendations can 
be defined. The concept of diagnostic nodes (Dodes) has been developed [28, 29] to allow for a 
cross-comparison of recommendations in decision-tree format and has been applied in a clinical 
setting [30, 31]. Dodes are organized into decision trees using pre-defined categories. Standardized 
nomenclature of parameters and recommendations is a prerequisite for automated comparisons and 
an unbiased evaluation. Based on Dodes and the objective consensus methodology [29], consensus 
and heterogeneity were analysed (Fig. 1). 
Hospitals with an interdisciplinary neuro-oncology unit including at least full-time service of neuro-
surgery, radiotherapy and medical neuro-oncology with a dedicated neuro-oncology tumour board 
being represented in the Swiss Group for clinical cancer research (SAKK) were asked to participate in 
the study. Treatment recommendations for recurrent glioblastoma were collected without 
specifications in formatting. Free-text, Microsoft PowerPoint slides and hand-drawn diagrams were 
converted without changing content into treatment algorithms and after several bilateral exchanges 
defined as final by 1st of January 2015. These were again discussed among the participating centres. 
Two centres took patient preference explicitly into account; these were related to the decision for 
active treatment versus best supportive care (BSC). Despite these criteria being important for daily 
practice, they were eliminated for the analysis as they do not rely on a tumour board decision and of 
course should apply to every clinical decision. Similar criteria were fused into new comprehensive 
categories to simplify their usage and enable cross-comparability (i.e. the criteria fitness based upon 
performance status, co-morbidities and age). The resulting data were presented to the participants 
and minor corrections were applied. The interpretation by all participants resulted in the final 
discussion. 
 
Results 
In total, 8 Swiss centres (Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, St.Gallen, Zurich) 
participated and provided written or schematic information of their interdisciplinary local treatment 
strategy for recurrent glioblastoma. The original treatment algorithms included a total of 23 re-
treatment criteria and a list of 16 treatment options (Table 1, Fig. 2).  
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Processing and simplification 
As the considerable variability of the re-treatment criteria lead to an exponential rise in possible 
combinations, we simplified and integrated similar criteria with minor differences (Table 1). For 
example, the various thresholds of Karnofsky performance scale (KPS), age, Eastern cooperative 
oncology group performance status (ECOG) and the presence of co-morbidities were summarized as 
“fit” or “unfit”. Additionally, tumours were summarized as “resectable” or “non-resectable” according to 
their occurrence in eloquent areas and non-diffuse/localized distribution. Need for steroid use and 
symptomatic recurrent glioblastoma were merged to only one category. After simplification the trees 
were analysed with the so defined 8 essential criteria. All centres used resectability, fitness and time 
of recurrence as re-treatment criteria. Five centres (A, C-E, H) used the MGMT promoter status. 
However, we gathered no information which method and threshold for MGMT promoter methylation 
status was used in clinical practise. Four centres used tumour size (B, C, G, H) and unifocality (C, E, 
F, H). Only three and two centres, respectively, took symptoms (F, G, H) and complete resection of 
enhancing tumour (CRET) (A, B) into account.  
 
Re-treatment criteria 
All centres dichotomised their decision to actively treat recurrent glioblastoma with anti-tumour 
strategies by using the performance status (PS). Generally, “unfit” patients with a low PS were 
referred to BSC without offering active oncological treatment. The KPS and the ECOG were both 
reported. However, the lowest threshold for active anti-tumour re-treatment varied considerably (KPS 
from 50 to 90; ECOG 0-1) (Table 1). The same was true for age (between 50 and 75 years). 
However, age was only reported as a re-treatment criterion in 2 out of 8 centres.  
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Re-treatment options 
Five treatments were offered against recurrent glioblastoma in at least 4 centres (Fig. 2). These were 
the combination of re-operation with either TMZ or bevacizumab, monotherapy with either TMZ or 
bevacizumab and BSC. Interestingly, the time required to consider TMZ re-challenge ranged from 2 to 
6 months. Four centres additionally relied on the MGMT promoter methylation status to indicate an 
alkylator-based systemic treatment (TMZ or lomustine). Various re-treatment modalities and schemes 
were reported among the centres (Fig. 2). These included re-operation, re-irradiation, chemotherapy 
or immunotherapy, either as a monotherapy or as a multimodal treatment. For example, therapy 
varied by the combination of anti-neoplastic agents (bevacizumab, lomustine, temozolomide, 
bevacizumab/lomustine given in standard dosing), the schedule of re- irradiation (40 Gy in 1.66 
fractions, 42 Gy in 2.66 factions, 35 Gy in 3.5 fractions, 20 Gy in 2.0 fractions), re-irradiation with and 
without TMZ or bevacizumab and the method of re-irradiation (stereotactic radiotherapy (SRT), 3D-
conformal or intensity modulated radiotherapy). Furthermore, criteria like the localisation and 
distribution of the tumour (local/distant recurrence; single/multiple/diffuse recurrence; operable/not-
operable) were also taken into account (Table 1).  
 
Consensus treatment strategies 
Fig. 3 displays a comprehensive and condensed view of the re-treatment recommendations for 
recurrent glioblastoma where a majority recommendation was present (5 out of 8 centres; 63%). 
Seven out of 8 re-treatment criteria are implemented (time of recurrence, operability, size of the 
tumour, symptoms, fitness, MGMT promoter methylation and unifocality). The CRET criterion, which 
was only used in 2 centres (A, B), was not relevant to reach a majority treatment recommendation. 
Strong consensus was generally achieved in unfit patients. In all but one scenario 6 out of 8 centres 
recommended BSC instead of an anti-tumour treatment (fit=no). In contrast, in fit patients majority 
consensus was rare (fit=yes). Five out of 8 centres would treat fit patients with bevacizumab when a 
large non-operable early recurrent glioblastoma with an unmethylated MGMT promoter is present (* in 
Fig. 3). Additionally, TMZ would be the preferred recommendation (# in Fig. 3) in fit patients with a 
late recurrent, non-unifocal, non-operable and large glioblastoma with a methylated MGMT promoter 
with (5 out of 8 centres, 63%) or without clinical symptoms (6 out of 8 centres, 75%). 
 
Discussion 
In the absence of a standard of care for recurrent glioblastoma the aim of the present study was to 
investigate applied treatment strategies in 8 neuro-oncology centres in Switzerland. As we anticipated 
great heterogeneity we further aimed to identify clinical criteria which lead to individualized treatment 
decisions and to check if these criteria overlap between different centres. Our expectations in this 
regard were met as we identified various treatment modalities and multiple schedules as well as a 
plethora of various criteria for the treatment of recurrent glioblastoma. Based on these results, it is 
very unlikely that patients with recurrent glioblastoma obtain the same treatment recommendation 
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twice if they seek a second opinion in Switzerland. On the one hand this is due to individualized 
treatments for a given patient and takes patient- and centre-specific factors into account (i.e. 
availability of certain treatment options). On the other hand different recommendation can cause a 
decision dilemma for the patient.  
Original parameters could be processed and reformatted with the help of a standardized procedure 
(Dodes). This method enables the identification of the most common treatment recommendations for 
any specific parameter combination [29]. The process was feasible and produced the most commonly 
agreed upon treatment recommendations derived from heterogeneous recommendations. The data 
presented here might therefore serve as one basis to develop a nationwide treatment guideline. 
Moreover, areas of controversy or low overlap can be used to address clinically important questions 
for future clinical trials. 
All centres used the PS to decide about the indication of a tumour specific therapy. PS was measured 
with the KPS and ECOG which are well known instruments of daily oncological practice [14]. 
Additionally, age was a relevant criterion to guide treatment in some centres. PS and age are 
established prognostic factors for first-line as well as for second-line treatments [14, 32-36]. Recent 
studies set a threshold of KPS 60% (corresponding to ECOG 2) as a prerequisite for tumour specific 
treatment interventions [4, 5, 37, 38] as inferior PS is associated with increased side effects from any 
intervention and lowers the chance of clinical benefit [14, 36, 39]. The greatest consensus in our 
analysis was identified in unfit patients corresponding to a low PS. These patients would be mostly 
referred to BSC as the strategy of choice independent of operability, MGMT promoter methylation or 
time of recurrence, among other criteria (Fig. 3). Accordingly, this approach represents a robust 
consensus recommendation. This result is not trivial, as three out of eight centres did not actively 
claimed BSC as a primary re-treatment modality even after several feed-back rounds (Fig. 2). 
However, we are confident that a low PS would lead to the implementation of BSC without additional 
tumour specific treatment in daily practise in all centres. This issue might reflect a limitation of the 
study that not all applied treatment strategies are specifically enumerated by the participants. 
Despite the negative prognostic impact of mental and cognitive decline [39] none of the centres 
reported mental status or a formal cognitive testing (i.e. MiniMental Status Exam) as an aid to decide 
about treatment for recurrent glioblastoma. It is tempting to speculate that the physicians felt they 
integrate all dimensions of neurological function in clinical decision making and do not need these 
scales for whatever reason (i.e. time consuming procedure). Co-morbidities and their formal 
investigation were also rarely taken into account (i.e. Charlson co-morbidity score) and none of the 
centres reported usage of a structured geriatric assessment [40-43]. Hence, the issue of fitness for re-
treatment in recurrent glioblastoma mostly relies on a subjective perspective of the physician. 
Various strategies of re-operation, re-irradiation, systemic therapy and multimodal treatments were 
reported [14]. Major level of consensus was reached for TMZ re-challenge in lesions with a 
methylated MGMT promoter even in the absence of a controlled trial at the time of investigation. Only 
recently, the DIRECTOR and the BELOB trial demonstrated the prognostic value of the MGMT-
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8 
promoter methylation for PFS-6 and PFS-9, respectively, with significantly better outcome in recurrent 
glioblastoma with a methylated MGMT promoter [11, 15]. However, the optimal time span between 
first-line and second-line TMZ at recurrence still remains elusive.  
The anti-angiogenic agent bevacizumab is approved for the treatment of recurrent glioblastoma in 
selected countries including Switzerland. Somewhat surprisingly, only in fit, non-operable patients 
with a large lesion and an unmethylated MGMT promoter a majority of centres (63%) would offer 
bevacizumab. No consensus was obvious in all other occasions, despite approval and its steroid-
sparing properties. The reason for this low overlap might be related to the absence of a controlled 
clinical trial for the use of bevacizumab in recurrent glioblastoma or the recently reported failure in the 
first-line treatment setting [4, 38]. Moreover, conflicting results about a negative impact on neuro-
cognition may also hamper widespread use of this compound [44, 45]. 
Re-irradiation alone or in combination with systemic treatment did not reach any consensus. In 
addition to the paucity of controlled clinical trial this might reflect heterogeneity of radiation dose and 
technique. Despite the low efficacy of re-irradiation as a monotherapy observed in a controlled phase 
II trial with PFS-6 rates of 3.8% [24] a second radiation either alone or in combination with systemic 
therapy still remained a salvage treatment in five out of eight centres. However, this applies only in a 
selected patient population with good prognostic criteria. Of note, the same is true for re-operation 
which is mostly recommended in combination with other treatments in 7 out of 8 centres. Additionally, 
a controlled clinical trial demonstrating efficacy of this approach is also lacking. However, positive 
prognostic criteria (KPS > 80, tumour size ≤ 50 ml, non-eloquent region) for the estimation of 
prolonged postoperative survival after re-operation have been reported [46]. In this regard it has to be 
mentioned that local treatment strategies are driven by the experience of the local physicians, the 
availability to diverse radiation techniques and the attitude of neuro-surgeons to offer glioblastoma 
resection at recurrence.  
 
Conclusion 
The neuro-oncologist may be equally soothed or unsettled by these results. For certain clinical 
scenarios, 8 centres provided 6 different treatment recommendations. This sheds an interesting light 
on the value and risk of obtaining a second opinion in this context. Despite experience and access to 
published literature, the interpretation and clinical implementation of this was very different among 
Swiss neuro-oncology centres.  
The application of a decision tree analysis (objective consensus) was able to identify decision criteria 
relevant in clinical practice across centres. Future trials and guidelines should take these criteria into 
account to ease the transition of trial results and recommendations into clinical neuro-oncology. 
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Table 1 
Overview of original re-treatment criteria, assessment procedures and the derived standardized 
criteria used for comparison. 
 
Fig. 1 Analysis by the objective consensus method 
Example of an early recurrent, small and resectable glioblastoma harbouring a methylated MGMT 
(mMGMT) promoter. For fit patients heterogeneous treatment options were recommended among the 
centres (A-H), whereas in unfit patients 6 out of 8 centres (A, B, E, G, H, F) suggested BSC and only 
two centres (C, D) recommended alternative treatments. Bev, bevacizumab; Lom, lomustine; OP, 
operation; TMZ, temozolomide; BSC, best supportive care; SRS, stereotactic radiosurgery; &, 
combined treatment; +, sequential treatment. 
 
Fig. 2 
Implemented treatment strategies among the centres A-H (cross, reported; white, not reported); OP, 
operation; SRS, stereotactic radiotherapy; Bev, bevacizumab; TMZ, temozolomide; RT, radiotherapy; 
LOM, lomustine; BSC, best supportive care.  
 
Fig. 3 
The most common recommendations tree reveals areas of consensus (at least 5 out of 8 centres, 
>63%) for patients who are unfit (A-F). The most common recommendation is best supportive care 
(BSC). Only on 3 clinical scenarios either bevacizumab (BEV, *) or temozolomide (TMZ, #) (B,E,F) is 
recommended by the majority of centres depending on the presence of symptoms. Only 7 out of 8 re-
treatment criteria (all but the CRET criterion, see Fig. 3) were relevant for achieving a majority 
recommendation. 
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Table 1 
re-treatment criteria assessment simplified criteria 
performance status 
KPS </> 50; 60; 70; 90 
fit vs. unfit 
ECOG </= 1 
good/bad 
age </> 50 years; </> 75 years 
tumour volume >/> 65 ml; </> 1.5 cm 
operable vs.  
not operable 
rGBM characteristics 
new/distant lesion 
diffuse / local lesion 
resectable (yes/no) 
single/ multiple lesions 
growth kinetics (slow/rapid) 
time from last  
TMZ treatment 
</> 2;4;6 months 
early vs. late 
time from last radiotherapy </> 6 months 
re-resection total; subtotal CRET vs. non-CRET 
symptomatic rGBM yes/no symptomatic vs. 
asymptomatic steroid use yes/no 
methylated  
MGMT promoter 
yes/no unchanged 
Among 8 neuro-oncology centres 23 re-treatment criteria were disclosed. Based on 
unification and simplification similar criteria were partially re-named and merged. 
Abbreveations: KPS, Karnofsky performance status; ECOG, Eastern Cooperative 
Oncology Group performance status; rGBM, recurrent glioblastoma; CRET, complete 
resection of contrast enhancing tumour; TMZ, temozolomide; vs., versus 
